Press Releases
June 05, 2020 Devonian Health Group Announces Change to its Board of Directors
May 21, 2020 Devonian Health Group Announces the nomination of Dr André P. Boulet to the American Botanical Drug Association
May 04, 2020 Devonian Health Group Announces the Closing of $1,805,000 Non-Brokered Financing
April 24, 2020 Devonian Health Group Announces an Increase to its Non-Brokered Financing to $2,000,000
February 11, 2020 Devonian Health Group Announces R-Spinasome® anti-aging technology global sales and marketing partnership
January 29, 2020 Devonian issues settlements of interest due to a debenture holder and announces the results of the annual general meeting of shareholders
January 23, 2020 Devonian Health Group Announces presentation to the World Conference on Ageing and Gerontology and a correction on expiry date of warrants
January 16, 2020 Devonian Health Group Announces Cannabis Cutting-Edge Extraction Equipment in its Montmagny Facility
October 03, 2019 Devonian Health Group Obtains Cannabis Research License from Health Canada
August 21, 2019 DEVONIAN ANNOUNCES THE CLOSING OF A $315,000 PRIVATE PLACEMENT AND AN ADDITIONAL LOAN OF $500,000
July 23, 2019 Dr George G. Zhanel joins Devonian’s Cannabinoids Scientific Advisory board
April 02, 2019 Devonian Healthcare Group Reports Key Financial Results for Quarter Ended January 31, 2019
April 01, 2019 Devonian Health Group issues Securities In Interest Settlement Due To Debenture Holders and grants options
January 31, 2019 Devonian Announces voting results of the Annual General and Special Meeting
January 23, 2019 Devonian Health Group Announces the refinancing of the loan on its pharmaceutical facility
December 20, 2018 Devonian Health Group Announces 2018 Annual General Shareholder’s Meeting
October 03, 2018 Devonian Health Group Receives 2018 Best Anti-Aging Skin Treatment Technology from LUX Life Magazine.
September 04, 2018 Devonian Health Group announces the completion of the second tranche of its previously announced private placement and provides an update.
August 08, 2018 Devonian Health Group provides an update on its previously announced private placement.
July 31, 2018 Devonian Health Group Announces issuance of European Patent for its Purgenesis™ anti-aging treatment.
July 19, 2018 Devonian Health Group announces Non-Brokered Financing by way of a private placement of Convertible Debenture.
July 18, 2018 Devonian Healthcare Group Reports its First ever Revenues: Key Financial Results for Quarter Ended April 30th, 2018
June 29, 2018 Devonian Announces Grant of Options
June 28, 2018 Devonian Announces the Signing of a Non-Binding Letter of Intent with Folia Biotech to develop FB-631 in cancer immunotherapy.
June 27, 2018 Devonian Health Group Announces issuance of United States Patent for its Purgenesis™ anti-aging treatment.
June 07, 2018 Purgenesis™: Commercializing a Skin-Care Revolution
May 16, 2018 Devonian Health Group Announces Canadian Patent for its Purgenesis™ anti-aging treatment
March 20, 2018 Devonian Announces Grant of Options
February 26, 2018 Devonian announces the trading of its shares will resume on Tuesday February 27th, 2018
February 12, 2018 Aspri Pharma Canada Inc. Announces Acquisition of Subordinate Voting Shares of Devonian Health Group Inc.
February 01, 2018 Devonian Announces Acquisition of Altius Healthcare
January 15, 2018 Devonian Announces voting results of the Annual General and Special Meeting
November 16, 2017 Devonian Announces the Filing of New Patent Application for ThykamineTM
November 09, 2017 Devonian Announces Initiation of Phase IIa Clinical Trial of ThykamineTM in Adult patients with Mild-to-Moderate Atopic Dermatitis
September 28, 2017 Devonian Health Announces PurgenesisTM anti-aging treatment marketing and distribution partnership.
September 14, 2017 Devonian Health Group to present at GCFF (Global Chinese Financial Conference) 18th annual conference
September 06, 2017 Devonian Health Group’s Purgenesis™ anti-aging derma-cosmeceutical treatment is now recognized through the Canadian Dermatology Association Skin Health Program
July 13, 2017 DEVONIAN HEALTH GROUP INC.- DEVONIAN ANNOUNCES CLOSING OF PRIVATE PLACEMENT
July 07, 2017 DEVONIAN HEALTH GROUP INC.- DEVONIAN ANNOUNCES GRANT OF OPTIONS
June 22, 2017 DEVONIAN HEALTH GROUP INC.- DEVONIAN ANNOUNCES PLANS FOR ITS DERMATOLOGY PROGRAM OF THYKAMINE
June 21, 2017 DEVONIAN HEALTH GROUP INC.- DEVONIAN ANNOUNCES ISSUANCE OF ONE NEW KEY PATENT AND THE GRANTING OF A TRADEMARK
May 18, 2017 DEVONIAN HEALTH GROUP INC.- LISTING OF ITS SHARES ON THE TSX VENTURE EXCHANGE
April 27, 2017 ORLETTO CAPITAL INC. / DEVONIAN HEALTH GROUP INC. – END OF ITS PREVIOUSLY ANNOUNCED PUBLIC OFFERING
February 03, 2017 ORLETTO CAPITAL INC. / DEVONIAN HEALTH GROUP INC. – RECEIPT FOR ITS AMENDED AND RESTATED PROSPECTUS
November 25, 2016 ORLETTO CAPITAL INC. / DEVONIAN HEALTH GROUP INC. – RESULTS OF THE VOTES FROM THE ANNUAL GENERAL MEETING OF ORLETTO
November 09, 2016 ORLETTO CAPITAL INC. / DEVONIAN HEALTH GROUP INC. – RESULTS OF THE VOTES FROM THE ANNUAL GENERAL MEETING OF DEVONIAN
November 07, 2016 ORLETTO CAPITAL INC. / DEVONIAN HEALTH GROUP INC. – DEVONIAN APPOINTS DR JEAN-CLAUDE TARDIF AS CHAIRMAN OF SCIENTIFIC ADVISORY BOARD
August 23, 2016 ORLETTO CAPITAL INC. / DEVONIAN HEALTH GROUP INC. – FINANCING BY WAY OF LONG FORM PROSPECTUS
April 26, 2016 ORLETTO CAPITAL INC. / DEVONIAN HEALTH GROUP INC. – AGREEMENT IN PRINCIPLE
May 20, 2015 ORLETTO CAPITAL INC. / DEVONIAN HEALTH GROUP INC. – AGREEMENT IN PRINCIPLE